Dosing and Titration

Dosing Designed for Patients

95% of GRALISE patients achieved an 1800 mg dose within 2 weeks.1

Discontinuation due to adverse events (AEs) during the 2-week titration period was 3.6% for GRALISE and 3.0% for placebo.1

Overall rates of discontinuation due to AEs were 9.7% for GRALISE vs 6.9% with placebo.2

Based on pooled analysis from PHN placebo-controlled clinical trials (n=723); 93.4% of placebo patients also achieved an 1800 mg dose within 2 weeks.1

With its unique gastroretentive technology and 900 mg strength option, patients can achieve the optimal daily dose of 1800 mg with just 2 tablets.2

900 mg strength enables optimal daily dosing of 1800 mg with just 2 tablets

Dosing for patients with renal impairment

Creatinine Clearance
(Once daily with evening meal)
≥601800 mg
30 to 60600 mg to 1800 mg
<30GRALISE should not be administered
Patients receiving hemodialysisGRALISE should not be administered


  1. Irving GA, Sweeney M. Tolerability and safety of gastroretentive once-daily gabapentin for the treatment of postherpetic neuralgia. J Pain Res. 2012;5:203-208.
  2. GRALISE. Prescribing information. Almatica Pharma LLC; 2023.
Savings card

Most patients pay as little as $20*

Download savings card
*Applies to commercially insured patients. Individual costs may vary. Program eligibility and restrictions apply.

Gabapentin is a controlled substance in several states. Contact local authorities for more information. Advise patients to take GRALISE only as prescribed.